

OSPO

1634

PATENT



Case Docket No. ELITRA.009A
Date: March 18, 2003


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Forsyth, et al.
Appl. No. : 09/741,669
Filed : December 19, 2000
For : GENES IDENTIFIED
AS REQUIRED FOR
PROLIFERATION OF
E. COLI
Examiner : Frank Wei Min Lu
Group Art Unit : 1634

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on

March 18, 2003

(Date)


Daniel Hart, Reg. No. 40,637


TRANSMITTAL LETTER

**United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202**

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with five (5) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Daniel Hart
Registration No. 40,637
Attorney of Record



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Forsyth, et al.)	Group Art Unit 1634
App. No.	:	09/741,669)	
Filed	:	December 19, 2000)	
For	:	GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION OF E. COLI)	
Examiner	:	Frank Wei Min Lu)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing five (5) references that are also enclosed. This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).


CERTIFICATION UNDER 37.C.F.R. 1.97(e)(1) AND 1.97(e)(2)

I hereby certify that each item of information contained in the Information Disclosure Statement was either first cited in a communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of the Information Disclosure Statement, or, to the knowledge of the person signing this Certification after making reasonable inquiry, was not known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 18, 2003

By: 
Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.009AAPPLICATION NO.
09/741,669SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Forsyth, et al.FILING DATE
December 19, 2000GROUP
1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
	1	Branch, A. D. 1998. A good antisense molecule is hard to find. <i>TIBS</i> , 23:45-50.
	2	Dove, A. 2002. Antisense and sensibility. <i>Nature Biotechnology</i> , 20:121-124.
	3	Gucev, et al. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β 2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 56(7):1545-1550.
	4	Lebedeva, et al. 2001. Antisense oligonucleotides: Promise and reality. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 41:403-419.
	5	Sofia, et al. "Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228916.

S:\DOCS\DOH\DOH-7344.DOC:dmb
031703

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.